Christina T. Loguidice

A panel of breast cancer experts discuss a variety of new and emerging agents to treat patients with advanced or metastatic HER2-positive breast cancer with disease progression following treatment with at least 1 anti-HER2 therapy.

During an OncLive Peer Exchange®, a panel of orthopedic experts provided a comprehensive overview of these tumors, including their epidemiology and differential diagnosis, optimal clinical workup, and the role of surgical management.

During a recent OncLive Peer Exchange®, a panel of hematology-oncology experts discussed some of the challenges surrounding the integration of biosimilars in clinical practice using the breast cancer landscape.

A panel of experts in breast cancer discuss the emergence of alpelisib, review data from the BYLieve trial, discuss the role of everolimus, and review the emergence of oral taxanes.

A panel of hematology-oncology experts discuss the emergence of biosimilar use in oncology.

During a recent OncLive Peer Exchange, a panel of experts in advanced prostate cancer provided their insights on how best to employ 6 therapies that are enabling men with mCRPC to live longer.

A panel of experts provide their insights on how and when they are using novel imaging versus conventional imaging. They also discuss the data regarding the FDA-approved AR-targeted therapies, how they select between them, and their strategies for mitigating any adverse events.

During a recent OncLive Peer Exchange®, a panel of experts in adult and pediatric leukemia provided insight on how they use minimal or measurable residual disease (MRD) to guide treatment decisions, including transplantation and choice of therapy in patients who demonstrate MRD positivity after induction and first- and subsequent-line therapies.

The degree to which nature and nurture affect disease has long been debated in medicine, and it is an issue that esteemed breast cancer researcher and medical oncologist Joyce A. O’Shaughnessy, MD, has been working to unravel for her patients throughout a career that spans more than 30 years.

During a recent OncLive Peer Exchange®, a panel of experts in adult and pediatric leukemias provided an update on minimal residual disease testing in acute lymphoblastic leukemia.

During a recent OncLive Peer Exchange®, a panel of hematologic cancer experts discussed several novel treatments that are changing the relapsed/refractory mantle cell lymphoma treatment landscape, including Bruton tyrosine kinase (BTK) inhibitors, BTK combinations, and chimeric antigen receptor T-cell therapy.

Although considerable progress has been made in treating diffuse large B-cell lymphoma since the advent of chemoimmunotherapy, approximately 33% of patients still develop relapsed/refractory disease, which is associated with considerable morbidity and mortality.

During a recent OncLive Peer Exchange®, a panel of experts sought to answer several key questions regarding the management of advanced, hormone receptor–positive breast cancer, particularly with CDK4/6 inhibitors.

The treatment paradigm for patients with prostate cancer is evolving, with the growth of approved and newly developed agents and an increased understanding of the role of genomic drivers.

Immune checkpoint inhibitors have yielded modest improvement in small cell lung cancer (SCLC), but have already reshaped the management of this tumor type and helped open the door to the exploration of other, potentially more effective treatment approaches, according to a panel of thoracic oncology experts who discussed the treatment horizon for SCLC in a recent OncLive Peer Exchange® panel.

PARP inhibitors are poised to acquire a stronger foothold in the frontline setting for advanced ovarian cancer, for which chemotherapy remains the backbone of treatment, according to a panel of gynecologic oncology experts who discussed the issue during an OncLive Peer Exchange® held during the European Society for Medical Oncology Congress 2019.

During a recent OncLive Peer Exchange, a panel of leukemia and lymphoma experts discussed emerging BTK inhibitors.

During a recent OncLive Peer Exchange® program, a panel of leukemia experts provided an overview of these agents and shared their perspectives on how clinicians can incorporate them into their clinical practice.

With a variety of available agents in follicular lymphoma, determining which treatments to choose and how best to sequence them can be challenging.

During an OncLive Peer Exchange®, a panel of pancreatic cancer experts discuss how they select between first- and subsequent-line cytotoxic regimens and strategies they use to reduce toxicity, including dose modifications and alternative combinations. They also provide insights on some of the emerging therapies in clinical trials for advanced pancreatic cancer.

Five melanoma experts discuss findings from several exciting studies presented at the 2019 ASCO Annual Meeting that are helping to change the way patients with malignant melanoma are treated.

Emerging immunotherapy combinations have offered a strong challenge to sunitinib (Sutent) in the setting of frontline advanced clear cell renal cell carcinoma.

During a recent OncLive Peer Exchange®, a panel of breast cancer experts discussed how they are using CDK4/6 inhibitors in their practices. They shared their insights on the tolerability and toxicity profiles of the FDA-approved CDK4/6 inhibitors, how they choose which agents to use for each patient, and how they select the next line of therapy after the patient progresses.

During an OncologyLive Peer Exchange, the panelists discuss some of the challenges they face when conducting molecular testing, including determining which patients to test, when to test, and how to test to ensure that no golden tickets, such as NTRK gene fusions, are missed. They also discuss the data surrounding TRK inhibitors and their experiences using these agents.

The development of targeted therapies, including bevacizumab (Avastin) and 3 PARP inhibitors, is changing treatment paradigms for women with epithelial ovarian cancer.

During a recent panel discussion, neuroendocrine tumor experts Simron Singh, MD, MPH, and Jonathan R. Strosberg, MD, provided insight on which patients are the best candidates for these approved treatments and how to sequence therapy to optimize outcomes.

During an OncLive Peer Exchange®, a panel of CLL experts review findings from studies presented at the 2018 American Society of Hematology meeting in December: iLLUMINATE, Alliance A041202, and ECOG E1912.

During a recent OncLive Peer Exchange®, a panel of breast cancer experts discussed emerging agents in triple-negative breast cancer, which include an anti–PD-L1 antibody, 2 PARP inhibitors, and a novel antibody–drug conjugate.

During a recent OncLive Peer Exchange®, panel members discussed the use of HER2-targeted therapies in patients with early-stage HER2-positive breast cancer in the neoadjuvant and adjuvant settings.

Clinical trial evidence is building for moving checkpoint blockade immunotherapy forward in the treatment timeline for non–small cell lung cancer, but improving patient selection for these therapies remains a key challenge.